Viatris stock
VTRSNASDAQViatris Inc., HealthcareISIN US92556V1061
55Score 55 out of 100, Neutral
Price and trend
82 / 100
Price history
+88% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 30% above it.
Since September 2025 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 75).
The price is at its 52-week high. Largest decline in 20 years: 90% (April 2015 to April 2025).
Chart figures for advanced users
- SMA 50$17.96
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$16.16
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)75
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$10.19
- The lowest closing price of the last twelve months.
- Resistance$21.06
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Viatris Inc. belongs to the Drug Manufacturers (Specialty & Generic) industry (United States) and, with a market value of $24.14B, is number 13 of 78 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $14.3B (down 3% year on year) and a loss of $3.51B.
- For fiscal 2026, analysts expect on average revenue of $14.78B (up 3.3%) and adjusted earnings per share of $2.51 (up 6.5%).
Show more
- MEQIRI Score 55 out of 100 (Neutral): rank 340 of 714 in Healthcare, median 53.
- Our model puts fair value at $38.54, with the price 45% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Below fair valuePrice 45% below the fair value of $38.54.Valuation 93
Weaknesses
- DilutionShare count up 95% since 2020.Capital allocation 18
- Loss-makingLoss of $607.8M over the last 12 months.Fundamentals 47
Its standout strengths are valuation and momentum, while profitability and capital allocation hold the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among stocks ranked 101 to 1,000.
From 2016 to 2025, 23 in 100 such stocks fell 30% or more within a year, against a group average of 15 in 100.
What drives the risk
- price up very strongly over the past year
- weak fundamentals
What lowers it
- price near its 52-week high
- stable momentum
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $29.65 and expensive above $55.06 (uncertainty medium, based on the price swings of the past year).
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $31.91, at 7.8% it would be $48.51.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 4.3% on the twelve months before. Revenue has grown strongly since 2005, at around 14% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 35%, operating −19%, net −25%. Last 12 months: net −4%.
Debt & balance sheet
latest quarterDebt is moderate, but interest coverage is weak. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 25 Feb 2027in 105 days
- Last reported
- 5 Nov 2026EPS reported $0.71 (expected $0.64)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $2.51−0.1%
- Revenue
- $14.78B−0.1%
- Earnings per share
- $2.71+1.1%
- Revenue
- $15.25B+1.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook raised
Share price after the results: −6.9%Midpoints of the 2026 guidance raised across all key metrics; according to an analyst, revenue by $50 million and EBITDA by $100 million.
“So at the midpoint of 2026 guide, you're raising revenue by $50 million, but EBITDA by $100 million.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 6 Aug 2026 (fiscal Q2 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases in the last 6 months. One insider sold, $809,784 in total.
Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.
- Campbell PaulSale
25 Jun 2026, See Remarks
- Shares
- 50,076
- Price
- $16.17
- Value
- $809,784
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Viatris
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 55
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Drug Manufacturers (Specialty & Generic)
The next larger and next smaller companies by market value
- HaleonHLN $40.35B61
- ZoetisZTS $33.55B75
- Divi's LaboratoriesDIVISLAB.NS $32.21B75
- Hansoh Pharmaceutical Group3692.HK $26.55B79
- Torrent PharmaceuticalsTORNTPHARM.NS $19.33B63
- PharmaEssentia6446.TW $16.81B71
- Shionogi4507.T $16.34B81
- IpsenIPN.PA $15.4B75
ETFs that hold Viatris
Held by 39 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Nasdaq US Biotechnology UCITS ETF2B70 | 1.43% | 0.35% | €1.21B |
| Harbor Health Care UCITS ETF AccW311 | 0.93% | 0.89% | €11.61M |
| WisdomTree US High Dividend UCITS ETF AccWTD9 | 0.92% | 0.29% | €182.46M |
Show 5 more
| WisdomTree US Equity Income UCITS ETF EUR Hedged AccWTDY | 0.88% | 0.35% | €204.34M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.49% | 0.30% | €944.34M |
| Goldman Sachs ActiveBeta Paris-Aligned Sustainable US Large Cap Equity UCITS ETFGACA | 0.35% | 0.14% | €135.41M |
| iShares MSCI USA Small Cap CTB Enhanced ESG UCITS ETFSXRG | 0.33% | 0.43% | €2.48B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.33% | 0.15% | €592.11M |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 18 Oct 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.